AJR Am J Roentgenol. 2016 Jul;207(1):4-14. doi: 10.2214/AJR.15.15480. Epub 2016 Apr 11.
Howard SA1,2, Krajewski KM1,2, Jagannathan JP1,2, Braschi-Amirfarzan M1,2, Tirumani SH1,2, Shinagare AB1,2, Ramaiya NH1,2.
OBJECTIVE: As cancer care becomes increasingly personalized and patients with metastatic disease live longer, oncologists' approach to drug toxicity is also evolving.
CONCLUSION: This article aims to broaden the radiologist's understanding of imaging-evident toxicity by describing how oncologists grade toxicity, exploring toxicity as a biomarker of treatment response, discussing the effect of toxicity in patients who are candidates for metastasectomy, and illustrating how combining drugs of varying classes amplifies toxicity.